Introduction
Growing awareness of the need to improve not only the effectiveness but also the cost-effectiveness of health care interventions has produced various streams of demand for economic evidence. First, there are requests for measures of the overall resource or cost impact of a particular health problem, leading to cost-ofillness and`global burden' studies. Recently, attention has focused on some of the non-health care costs. Whilst informative, cost-of-illness studies can be rather distracting and perhaps even misleading. Second, there are demands for economic evaluations of particular treatments or policies, generating cost-effectiveness and similar analyses, either carried out alongside clinical trials or independently. Third are searches for new service and health system con®gurations that can improve the ef®ciency of use of available resources. Examples of such changes with potential ef®ciency consequences are the sweeping managed care developments in the US and the less dramatic developments iǹ sectorization', privatization of provision and care programming in some other countries. Each of these demand streams is quite well represented in the literature on depression (or on mental health broadly) and its treatment.
There is a fourth set of demands for economic evidence ± intersecting with the other three ± which is not at all well represented. This is the need for economic insights to help countries that are less developed or`in transition' (such as many parts of central and eastern Europe) to provide decent and affordable health care.
The costs of depression Sartorius [1 . ] describes depressive disorders as a major public health problem de®ned by the essential criterion that`there should be an effective intervention that will diminish or eliminate the problem' (p. 8). Four criteria for public health importance are discussed: frequency, severity, treatment options and trends of prevalence. The severity of depression and its consequences are discussed. Severity is divided into indirect measures such as frequency of suicide or disruption of a patient's social environment and direct measures such as the cost of treatment. Depression is argued to be probably the most important risk factor for suicide: two-thirds of all suicides are committed by people suffering from depressive disorders. The paper also discusses the disability resulting from depressive disorders and indeed that they`cause more disability than most chronic physical disorders' (p. 9).
Depression is more prevalent than disorders such as schizophrenia which are often seen as more serious, but has generally been found to have lower aggregate health care costs. Berto et al.
[2] reviewed cost-of-illness estimates for depression in the USA, UK and Italy. Despite the (successful) emphasis in each of these countries on treating mental health problems in community settings, the most important contributor to the direct costs of depression was still hospitalization, accounting for around half the total in the UK and three-quarters in the US. Drugs are a small part of the total (2±11% in most studies).
A poster by Das Gupta and Guest [3] presented cost-ofillness estimates for bipolar affective disorder, also concluding that the cost of drugs is small ± less than 2% of the total cost of GP-prescribing for all psychiatric conditions in the UK and about 5, 14 and 14%, respectively, of general psychiatric inpatient, outpatient and general community team costs. Bipolar affective disorder is estimated to cost UK society £2.1 billion annually (1999/2000 prices), 10% of which is due to NHS resource use and 5% to non-healthcare resource use. Indirect costs account for the remainder, linked to the high unemployment rate for people with bipolar disorder.
Brunello et al. [4 . ] review the interesting area of depression and sleep disorders, which result in signi®cant costs to society, both direct costs (visits to doctors, cost of sleeping medication, complications from use of these medications) and indirect costs (accidents, quality of life). The relationship between depression and sleep disorders is complex. What seems to be clear, however, is that persistent sleep disturbance is associated with a signi®cant risk of both relapse and recurrence and an increased risk of suicide, and that certain sleep variables can predict treatment response and clinical course. The role of antidepressants in sleep is discussed. Some but not all suppress rapid eye movement sleep, and other areas of the sleep cycle may be affected. The majority of antidepressants are associated with signi®cant improvement in subjective sleep that may result in both increased treatment adherence and reduced treatment costs.
Looking across all health problems, Bloom et al. [5] rightly criticize cost-of-illness studies for their inconsistency of method, perspective and coverage, and for the wide range of estimates they produce. Interestingly, they show that estimates for the overall costs of depression show less variability across studies (in the US) than do estimates in most other diagnostic areas.
Stephens and Joubert [6] point to another dif®culty ± that most cost-of-illness estimates are based on only medically treated, diagnosed disorders, whereas un-treated states such as`distress and depression' can still be very burdensome to the individuals concerned and to society. Much of the economic`burden' is experienced through lost earnings (to the individual) and lost productivity (to society), impacts for which the importance can also be clearly seen in the evaluation literature (see below). Another source of underestimated impact identi®ed (and measured) is misplaced (or missed) attribution of indirect costs to speci®c illness categories.
Cost-of-illness and similar studies tell us nothing about cost-effectiveness and therefore can provide decision makers with little or no guidance as to how to allocate available resources between competing demands or needs. Bloom et al. [5] in fact question how often decision makers actually use such studies. These studies do, however, serve two purposes. The ®rst is to describe the breadth of impact of a disorder. It is clear from the accumulated evidence on depression that there are not only substantial health care costs associated with treatment and support, but also high ± and almost certainly much larger ± costs falling to other service agencies, to the economy through lost productivity and to society at large. In acting upon evidence on the costeffectiveness of depression treatment, decision makers should therefore be cognizant of the wide span of potential economic impacts. Second, cost-of-illness estimates remind us that economics evidence is necessarily context-speci®c. The cost impact of depression is closely tied to the structure of the health care system, and economic data and ®ndings do not always travel well between health systems. This, too, needs to be borne in mind when looking at the cost-effectiveness evidence.
Employment and earnings costs
Depression has one of its most signi®cant economic impacts through its effects on work performance and absenteeism. Over the years, different studies have produced markedly different estimates for these employment or productivity costs, re¯ecting differences in methodology. For example, one widely quoted study suggested that lost work days due to affective disorders cost the US economy an amount equivalent to just over half the total health care costs [7] , while another concluded that the employment-related impacts of depression were 2.5 times larger than the health care costs [8] . Few studies, however, have explored the costs of reduced productivity whilst at work, even though this is potentially a substantial consideration in relation to people with mild/moderate depression [9] .
Marcotte and Wilcox-Go È k [10 . . ] provide an excellent review of the evidence on employment and earnings losses due to mental illness. This is not a comprehensive review of every study ever completed, but a brief canter through the history of such attempts followed by a focused look at the methodological approaches and policy implications of the key studies. Koopmanschap [11] offers a helpful (mainly methodological) commentary on their work. Four conclusions emerge from Marcotte and Wilcox-Go È k's review. First, the employment and earnings losses are large and substantially greater than the direct health care costs. Second, because health insurance coverage in the US and some other countries is often tied to employment, people with mental health problems face double jeopardy: income losses and inadequate insurance cover. Third and more positively, treatments that are effective in reducing the relapse probability can have a large pay-off. Fourth and worryingly, the different approaches used by economists to value employment losses generate widely different estimates but also healthy debate about methodologies. The preferred approach depends a lot on whether one focuses on the private costs borne by people who are ill or the broader societal costs.
Simon et al. [12 . . ] give considerable attention to the employment effects of recovery from depression, carrying out secondary analyses of randomized controlled trial (RCT) data collected in Seattle. Data from the 12-month assessment were used to categorize patients as remitted, improved but not remitted, or persistently depressed. Adjustments were made for baseline symptoms (severity of depression and medical comorbidity) and other factors before examining the link between clinical improvement and employment patterns. Patients who improved were more likely to continue in paid employment (if working at baseline) or to return to work (if not originally employed). Clinical improvement was also associated with fewer work days lost through illness, but not with the typical number of hours worked per week. For those whose symptoms improved there was a marginally signi®cant reduction in health care costs, although not until the second year after initiating antidepressant treatment. The impact on employment is therefore both larger and more immediate.
The signi®cance of these longitudinal ®ndings ± in contrast to the generally cross-sectional evidence that has previously been reported ± is that they hint at causal connections rather than mere associations. The ®ndings, however, apply only to patients with mild/moderate depression treated with antidepressants.`Patients whose depression goes untreated or unrecognised' and those with more severe symptoms might not enjoy the same economic bene®ts.
Socio-economic correlates
The role of the social environment in the aetiology of depression has attracted a great deal of interest. It is well established that adverse life events, particularly those characterized by loss, increase the risk of and episodes of depression [13, 14] , and genetic factors also in¯uence the risk of onset of major depression [15 . . ]. The in¯uence of socio-economic deprivation on the prevalence and outcome of depression in primary care is studied by Ostler et al. [15 . . ] . After discussing previous evidence on the links between the prevalence of depression, area deprivation, individual characteristics such as unemployment and employment grade, they turn to their own empirical evidence for 18 414 patients attending 55 representative practices in southern England. They ®nd that the socioeconomic deprivation of a general practice locality is a powerful predictor of the prevalence and persistence of depressive symptoms. A widely used measure in England ± the Jarman under-privileged area score ± accounted for 48% of the variance between practices in the prevalence of depressive symptoms (on the Hospital Anxiety and Depression Scale). The effect of deprivation appears to be exerted through its in¯uence on vulnerable individuals rather than on the whole population, although the study design does not make it possible to distinguish between the effects of`social cause' (living in a deprived area causes depression) and`social selection' (depressed individuals may move into deprived areas). The study has its limitations ± the practices were not randomly selected, depressive symptoms were self-reported and the measure of area deprivation was not exact because some patients might have lived in an adjacent area ± but it usefully contributes to our understanding of the causes and correlates of depression (including economic factors), and has implications for the equitable distribution of health care resources.
Treatment cost-effectiveness
Health economists have developed a number of techniques for evaluating interventions and treatments. Economic evaluation is the comparative analysis of alternative treatments or policies in terms of both their costs and consequences. Armed with such a de®nition, health economists have developed cost-effectiveness, cost-consequences, cost-utility and cost-bene®t analyses, each of which combines evidence on both costs and outcomes. These are well described in good health economics textbooks [16, 17] .
Most published economic evaluations of depression treatment are based on one of three research designs: mirror-image (before-after) comparisons; decision and Markov models constructed from a combination of observational (perhaps trial-based) evidence and expert opinion; and secondary analyses of naturalistic (often routinely collected) data. Prospective randomized trial evidence with an economics component ± a fourth design, and generally much to be preferred ± is still quite rare. During the period under review there appear to have been no mirror-image studies of depression treatment published, and so we say nothing further about what can anyway be a somewhat limited research design, and potentially a misleading one for decision makers if the design does not include contemporaneous controls.
Decision and Markov models
The purpose of a decision or Markov model is to simulate the clinical management of a disorder and thereby to estimate the costs and outcomes of two or more treatment or care arrangements. The structure and parameters of the model are taken from the clinical, epidemiological and economic evidence in the relevant literatures, from data collected in naturalistic settings and from completed randomized trials. Expert opinion is used to ®ll gaps in the empirical evidence base. Generally, models build on valid and previously reported data to synthesise an approximation of the unmeasured' [18 . ] (p. 557). Most people would see models as providing an indication of likely costs and outcomes in the absence of trial or other robust observational data, particularly to bring another treatment option into consideration, and to allow longer term projections to be made. Of course, if too much reliance is placed on expert opinion and too little on real world empirical data there could be concerns about bias, about unrealistic care arrangements being assumed and about the imputation of idealistic (over-optimistic) outcomes.
A recent modelling study concluded that mirtazapine was more cost-effective than amitriptyline and¯uoxetine in managing moderate and severe depression in the UK [19] . Meta-analyses of four controlled trials generated outcomes data for the model, and a panel of 10 general practitioners and three psychiatrists was consulted to arrive at estimates of resource use and absenteeism from work due to depression. The complete absence of resource use data in the trials (which is, surprisingly, still very common across the clinical literature) meant that the model had to rely entirely on expert views to project the costs. In these circumstances the precise methods used by the expert panel to arrive at their resource use estimates should perhaps have been described more fully.
Jones and Cockrum [18 . ] review 10`economic modelling studies' in the depression ®eld. The review is probably not comprehensive in covering every such study, and relates only to drug treatments, but it provides detailed and insightful comments that will serve as an invaluable source. The ®nal conclusions and recommendations are a little under-developed given that these authors had so usefully and carefully picked over the details of key studies in the ®eld. General criticisms of the reviewed models concern imprecision in the estimates (modelling studies need to test for the sensitivity of the results, but quite a few do not) and opacity of methods or assumptions (transparency of methods and assumptions is essential). Another limitation is that modelling tractability usually demands that the analysis focuses on a single outcome dimension, which is not necessarily a fault except when the choice of outcome measure has been constrained by what data are available or what judgements a panel of clinical experts can be expected to make.
Secondary analyses of naturalistic data
Two recent studies have conducted secondary analyses of data in order to explore cost-effectiveness questions. Panzarino and Xuan [20] compare¯uoxetine, sertraline and paroxetine in the USA, drawing on data for 1350 incident cases of depression, followed through complete episodes. Full medical charges were calculated from claims data (a limitation of the study) and drug charges separately measured. Three groups of patients were de®ned, depending on their initial selective serotonin reuptake inhibitor (SSRI). Medical resource utilization was similar for the three groups, after adjusting for (a somewhat crude measure of) case-mix severity but not for pre-SSRI service utilization or apparently for other factors. The scope for such analyses was severely limited by the nature of the data available for the study. Although service use patterns did not differ, pharmaceutical charges were higher for¯uoxetine patients.
More than 9000 patients were included in the study reported by Edgell et al. [21 . . ] which compared four cohorts of patients also drawn from an insurance claims database (with all the attendant limitations) categorized by treatment type: no therapy, psychotherapy, drug therapy and combination therapy (drug plus psychotherapy). Psychotherapy was broadly de®ned, as was drug therapy (including both SSRIs and tricyclic antidepressants (TCAs)), and there are of course well-known differences in costs and outcomes within these treatment groupings. Nevertheless, economic comparisons between the latter three treatment options remain rare in the mental health literature, and some aggregation of this kind is anyway essential for analytical tractability. A twostage econometric procedure (using the inverse Mills ratio approach) was employed to try to deal with any selection bias ± a perennial and sometimes fatal problem with secondary analyses of naturalistic data. As previous studies have shown ± and as found by Simon et al. [12 . . ] ± achieving good clinical outcomes with depressed patients does not necessarily reduce total health care costs. This interesting study reaches a number of conclusions. At the core is the ®nding that initiating treatment with drug therapy and combination therapy is more costly in terms of health care service use compared with no therapy or psychotherapy. Patients who begin on psychotherapy alone have higher mental health care costs but lower total health care costs, suggesting that this type of treatment impacts on co-morbid symptoms.
Cost-effectiveness studies based on prospective trials
The reasons for preferring the RCT to other designs are well known and do not need to be rehearsed here. Those reasons apply just as forcibly to economic as to clinical evaluations. We also need to recognize, however, the limitations of RCT-generated economic evidence in health services research which has particular pertinence to depression treatment. This is the danger of an unreal treatment setting for the trial, especially as so manỳ routine' care settings are poorly resourced and care services poorly coordinated. There may also be a related problem with patient selection, with trial designs either excluding many of the patients typically seen in routine practice (because of co-morbidities, or the inability to give informed consent, or the inability to complete trial instrumentation) or including a broader span of morbidities as part of the experimental enquiry.
Simpson et al. [22 . ] conducted an RCT of counselling with routine GP care compared with routine GP care alone to evaluate social and clinical outcomes, as well as medical and other service costs. Although both patients and GPs expressed positive views about the counselling, the RCT showed no clinical outcome differences at 6 or 12 months. The economic evaluation included a fully comprehensive costing of all health care and other services, but not the costs of lost employment. Receiving counselling increased primary care costs in the intervention period, without any offsetting savings in the remainder of the year. Counselling as a supplement to standard GP care was thus not found to be cost-effective in the medium term.
Sanne et al. [23] discuss the complexities of estimating the societal costs of depression and also point out that estimates differ a great deal. They look at two major studies in detail. The controversial Gotland study [24] claimed that improving the skills of general practitioners in the diagnosis and treatment of depressive disorders was associated with reductions in the use of psychiatric inpatient care and sick leave frequency, and helped to prevent suicides. In contrast, the Hampshire Depression Project (a RCT) found that an education programme for GPs did not increase recognition or recovery rates of patients with depressive symptoms [25] . Sanne and colleagues conclude from these two studies that it is very uncertain to what extent it is possible to reduce the societal costs of depression, and that health economics research should be given priority. It is not clear whether these two studies can easily be compared, however, since they differ considerably in many respects, including their locations, design (one a RCT and the other quasiexperimental), sample sizes and outcome measures.
The London Depression Intervention Trial compared antidepressant treatment (TCA ®rst line, SSRI possibly second line) for a year with couple therapy (conceptualizing the patients' depressive symptoms in interactional terms), comprising 12±20 sessions of around 50 min each [26] . Cost measurement covered all health and other services, but not informal care or lost employment. Sample size was small for an economic evaluation (less than 40 patients costed in the treatment period, less than 50 in the 2-year follow-up period). In the treatment period, couple therapy was signi®cantly more costly than the medications taken by the drug group, but the difference was almost exactly offset by reduced utilization and costs of hospital and community services. In the follow-up period, costs were (not signi®cantly) higher for the drug group. Alongside improvements on the Beck Depression Inventory, this suggests that couple therapy is cost-effective. More distinctive than any total cost difference between the groups was the cost composition: couple therapy accounted for 81% of the experimental group's costs, whereas drugs accounted for only 38% of the total for the control group.
Summary view of economic evaluations
The accumulated volume of economics evidence on depression and its treatment is now suf®ciently large to warrant the occasional review. An excellent and comprehensive example was offered a couple of years ago by Rosenbaum and Hylan [9] , and although reviews in such a fast moving ®eld can date quite quickly, this particular chapter is well worth a careful read. Crown's paper [27] is necessarily rather less ambitious, turning a conference presentation into a short paper, and concentrating on the SSRIs and TCAs. The paper nevertheless manages to range over quite a number of studies, and to discuss the advantages and weaknesses of different research designs. The paper reminds us that there is still ± amazingly and quite worryingly ± only one prospective RCT comparing SSRIs with TCAs that includes an economic evaluation. Is it any wonder that health care decision makers sometimes struggle to ®nd robust evidence to guide their actions?
The economics of systems changes
Managed care is the most widely discussed of recent systems changes, with potentially numerous implications for ways of working, outcomes and cost-effectiveness. It is an example of systems change which creates economic and other incentives to make treatment changes. Managed care is not exclusively a US phenomenon, of course, with many other health systems having many of the features of a managed care system for some long time [28] , although the breadth and variability of US experience ± and the accompanying research attention ± have attracted international interest [29] . Some of the consequences for depression treatment have been considered [30, 31] . Structural reforms at the macro level also have their effects in other systems, such as in the UK's National Health Service [32] .
Economics and global mental health issues
Mood disorders are responsible for a signi®cant disease burden globally. Using the measure of disability adjusted life years, Murray and Lopez [33] estimated that unipolar major depression was the fourth leading cause of disease burden in the world, and it will move up the`league table' over the next few decades. In the wealthier health systems of the world, depression is still under-treated, but in the rest of the world it is often almost completely neglected unless severe. The World Health Report to be published by the WHO in October 2001 is devoted to mental health and will undoubtedly emphasize both the scale of psychiatric morbidity and the extent of undertreatment.
Various studies of the prevalence of major depression suggest a rate of 2±5%, but the prevalence increases to around 10% among people who contact their general health service for any reason [1 . ]. The World Health Organization's Psychological Problems in General Health Care Study collected data in 15 centres across the world (more than 25 000 people attending general health services) and found that a mean of 10.4% suffered from depressive disorders. There was wide variation, from around 30% in Santiago, Chile, to 2.6% in Japan [34] . Sartorius [1 . ] notes that a study by the World Health Organization found that primary care attendees with depressive disorder had experienced a mean of 8 days of disability in the previous month compared with only 2 days in those without a psychiatric illness.`Taking the world as a whole, the disability associated with depressive illness results in the loss of almost 13 million years of life each year' (p. 9). This has obvious signi®cance in terms of economic loss and human suffering.
The co-morbidities so often associated with depressive disorders, both other psychiatric conditions and also physical conditions, worsen the prognosis. Effective (and cost-effective) treatments acceptable to patients are available, and are affordable, but Sartorius laments the fact that few patients actually receive them, either because they do not seek medical help, or are not given appropriate medication. Inaccessibility, inequity, stigma, poverty and the scandalously low priorities accorded mental health treatment in many countries are some of the most common reasons. Sartorius urges`public health authorities [to] take resolute action now to deal with this urgent problem', including addressing issues of education, access to care, stigma reduction, and assistance to families to help them bear the burden of disease (p. 11).
Recently the Institute of Medicine [35] reviewed the impact of mental health problems worldwide. Their wide-ranging volume demonstrates clearly how little is known about the economic impact outside the developed world, or about the cost-effectiveness of treatment options.
Chisholm et al. [36 . . ] did not focus exclusively on depression (although most sample members had a diagnosis of depressive illness). Their ®ndings, however, offer probably unique evidence on service use and costs in two districts of India and Pakistan. This study (of naturalistic, observational design) aimed to demonstrate cost-outcome methods in the evaluation of mental health care programmes in low-income countries. Four rural populations were screened for psychiatric morbidity. Those diagnosed with a common mental disorder were invited to seek treatment, and assessed prospectively on symptoms, disability, quality of life and resource use. The economic analysis was from a societal viewpoint; in addition to the costs of the health sector, time costs and out of pocket expenses of users and their (informal) carers were considered.`When all costs are combined, the magnitude of the economic impact of depression and anxiety becomes evident: in the Bangalore site, the cost . . . is Indian Rupees 700 per month, and in the Rawalpindi site . . . is more than Pakistani Rupees 3000 per month. To put this in context, this is equivalent to between 7 and 14 days of an agricultural worker's wages in India, and approximately 20 days in Pakistan [36 . . ] (p. 585). The authors conclude that`economic analysis in low-income countries is both feasible and practicable' (p. 585). They also suggest that factors such as health seeking behaviour of the local population(s), and demographic, cultural and socio-economic factors are likely to contribute signi®cantly to the overall effectiveness and cost-effectiveness of interventions for common mental disorders, including depression. Thus these factors are relevant to the planning of such interventions.
Conclusions
The realization has grown over recent years and across most health care systems that health care decisions need to pay attention to cost-effectiveness as well as effectiveness. This has generated a number of demands for economic insights. The volume of solid evidence from economics studies is still modest, but accumulating steadily and converging on core ®ndings. Encouragingly, the quality of the economics evidence is also improving noticeably. Almost all of the available evidence, however, comes from a few North American and West European countries. Consequently, although the accumulation of empirical material should begin to satisfy those decision makers looking for a sound evidence base (although many of them might be a little worried that there are so few RCTs with cost-effectiveness or similar components), there is still a long way to go. Most of the people in the world who suffer every day under the burden of depression (often also carrying considerable associated stigma) are living in circumstances where their chances of getting affordable, effective treatment are virtually zero.
